OTA International (Dec 2022)

Does prophylactic local tobramycin injection lower open fracture infection rates?

  • Arun Aneja, MD, PhD,
  • Matthew W. Kavolus, MD,
  • Robert J. Teasdall, MD,
  • Chandler R. Sneed, BS,
  • Richard W. Pectol, BS,
  • Alexander E. Isla, BS,
  • Arnold J. Stromberg, PhD,
  • William Obremskey, MD, MPH

DOI
https://doi.org/10.1097/OI9.0000000000000210
Journal volume & issue
Vol. 5, no. 4
p. e210

Abstract

Read online

Abstract. Objective: To determine whether local aqueous tobramycin injection in combination with systemic perioperative IV antibiotic prophylaxis will reduce the rate of fracture-related infection (FRI) after open fracture fixation. Other Outcomes of Interest: (1) To compare fracture nonunion rates and report differences between treatment and control groups and (2) compare bacterial speciation and antibiotic sensitivity among groups that develop FRI. Design: Phase 3 prospective, randomized clinical trial. Setting: Two level 1 trauma centers. Participants: Six hundred subjects (300 in study/tobramycin group and 300 in control/standard practice group) will be enrolled and assigned to the study group or control group using a randomization table. Patients with open extremity fractures that receive definitive internal surgical fixation will be considered. Intervention: Aqueous local tobramycin will be injected into the wound cavity (down to bone) after debridement, irrigation, and fixation, following closure. Main Outcome Measurements: Outcomes will look at the presence or absence of FRI, the rate of fracture nonunion, and determine speciation of gram-negative and Staph bacteria in each group with a FRI. Results: Not applicable. Conclusion: The proposed work will determine whether local tobramycin delivery plus perioperative standard antibiotic synergism will minimize the occurrence of open extremity FRI. Level of Evidence: Level 1.